Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Study Identifier:

331-10-236

ClinicalTrials.gov Identifier:

NCT03238326

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Will Be Recruiting

Subscribe to Updates

Study Details

Medical Condition

Schizophrenia

Study Drug

Drug: Brexpiprazole

Date

Aug 2017 - Jun 2025

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 13 - 17 Years

Requirements Information

Protocol Summary

To further characterize the long-term safety and tolerability of brexpiprazole in adolescents with schizophrenia

Study Locations

Location

Status

Location

Clinical Research Site #101

Dothan, Alabama, United States, 36303

Status

N/A

Location

Clinical Research Site #128

Anaheim, California, United States, 92805

Status

N/A

Location

Clinical Research Site #105

Culver City, California, United States, 90230

Status

N/A

Location

Clinical Research Site #103

Long Beach, California, United States, 90807

Status

N/A

Location

Clinical Research Site #136

Atlanta, Georgia, United States, 30331

Status

N/A

Location

Clinical Research Site #148

Kansas City, Kansas, United States, 66160

Status

N/A